Overview of August 2025 Approvals
In August 2025, the Ministry of Food and Drug Safety (MFDS) authorized clinical trials for 14 medical devices. The list ranges from traditional equipment like hyperbaric oxygen chambers and personal continuous glucose monitoring systems to cutting‑edge digital therapeutics, a virtual‑reality vestibular rehabilitation program and non‑invasive neurostimulators. Under MFDS regulations and the Digital Medical Products Act (effective January 2025), devices that require clinical trial data or involve software/AI must obtain MFDS approval. This month’s approvals underscore the rapid convergence of medicine and digital technology and will be of particular interest to pharmaceutical and biotech professionals looking to gauge market trends.
Key Medical Device
Hyperbaric oxygen chamber
Hyperbaric oxygen therapy supplies 100 percent oxygen in a pressurized chamber that is two to three times higher than normal atmospheric pressure. According to the Cleveland Clinic, this environment allows the lungs to absorb more oxygen, helping tissues heal and fight infections. The approved trial will explore whether hyperbaric oxygen therapy can improve perfusion of the ischemic penumbra and neurological outcomes in acute ischemic stroke patients. Results could expand the use of hyperbaric therapy beyond its current indications.
Rehabilitation software: sarcopenia, torticollis, AI chest‑X‑ray and VR vestibular rehab
Digital therapeutics are evidence‑based interventions delivered via software to prevent, manage or treat disease. They rely on behavioural or lifestyle changes and are being developed for conditions ranging from diabetes and heart failure to Alzheimer’s disease and depression. Five rehabilitation/treatment software devices received approval:
- Sarcopenia training and screening software: Sarcopenia is an age‑related loss of muscle mass and strength; adults lose roughly 3–5 % of muscle per decade after age 30, which impairs daily activities and increases fall risk. The approved trials will test a digital knee‑extensor strengthening program and the VAROrehave screening tool in multi‑centre, randomized studies.
- ACESO for congenital muscular torticollis: CMT is a condition in which shortened neck muscles cause a child’s head to tilt. Early physical therapy can correct the tilt, but untreated cases may result in permanent stiffness. ACESO aims to quantify and correct head tilt using gamified exercises tailored for children.
- AI chest‑X‑ray reporting: Computer‑aided detection systems process digital images (X‑ray, MRI, endoscopy, ultrasound) to highlight suspicious regions and assist physicians. The MC‑XR‑01 software generates draft chest‑radiograph reports, and the trial will evaluate its validity via a rater‑blinded, crossover design.
- VR vestibular rehabilitation program: The Vestibular Disorders Association notes that virtual reality can reduce vertigo and dizziness, improve gaze stabilisation and postural control. However, VR is not meant to replace traditional therapy and should be used under the supervision of a healthcare professional. The approved study will assess a VR‑based program in patients with dizziness due to vestibular dysfunction.
Personal continuous glucose monitoring system
A continuous glucose monitor (CGM) estimates your glucose level every few minutes through a tiny sensor placed under the skin and transmits the data wirelessly to a smartphone, insulin pump or receiver. Real‑time glucose trends help people make informed decisions about food, exercise and medication, reducing episodes of hypoglycaemia. The approved trial evaluates the accuracy and safety of the CareSens Air 2 CGM in children with type 1 and type 2 diabetes. Successful results would expand pediatric access to real‑time glucose monitoring.
Low‑level light therapy device
Phototherapy uses ultraviolet light to treat skin conditions. The Cleveland Clinic explains that light therapy can reduce symptoms of psoriasis and eczema and is safe for all ages; it is also a common treatment for newborn jaundice. The OLEC‑Patch® is a wearable low‑power light device designed for mild atopic dermatitis or psoriasis. A randomised, double‑blind trial will measure changes in skin symptoms, potentially paving the way for portable phototherapy solutions.
Tissue restorative biomaterials and facial suspension threads
As collagen and hyaluronic acid levels decline with age, skin loses elasticity and wrinkles deepen. Dermal filler injections plump up wrinkles, smooth lines and restore facial volume. Hyaluronic acid (HA) fillers, a naturally occurring substance in the skin, typically last six months to a year. August approvals include trials comparing Uptivo Lidocaine®, Restylane®‑L, Neuramis® Deep, Sculptra® and new biomaterials. In addition, facial suspension threads use absorbable barbed sutures to lift sagging skin and stimulate collagen, providing a minimally invasive facelift. The approved trials will assess the safety and non‑inferiority of the YOUR LINE and MINT Lift threads.
Neurostimulation devices (tACS and HM‑2)
One study targets early‑stage Alzheimer’s disease with transcranial alternating current stimulation (tACS). Unlike transcranial direct current stimulation, tACS delivers low‑intensity sinusoidal currents at a chosen frequency to interact with cortical oscillations. By entraining brain rhythms and inducing long‑term plasticity, tACS may modulate cognitive processes and is being explored in psychiatric trials. The trial compares gamma‑frequency (40 Hz) stimulation to sham stimulation. Another trial evaluates the HM‑2 neurostimulator in patients with major depressive disorder, further highlighting non‑pharmacologic approaches to mental health.
Conclusion and Outlook
The August 2025 list demonstrates how digital therapeutics, AI‑assisted diagnostics, wearable monitoring devices and non‑invasive neurostimulation are reshaping the medical device landscape. Addressing challenges such as sarcopenia, pediatric diabetes, chronic skin diseases and neuropsychiatric disorders requires a diverse toolkit. Each device on the MFDS approval list must generate robust clinical evidence to progress from trial to market. For industry professionals, these approvals signal where investment and innovation are heading and underscore Korea’s commitment to rigorous regulation and global competitiveness.
Request a quote: If you would like to request a quote or detailed consultation about medical‑device development, approval or clinical trials, please contact our team. Our experts can provide tailored guidance.
Subscribe to our newsletter: To stay informed about the latest MFDS approvals and industry trends, please subscribe to our newsletter. We deliver regular updates and insights relevant to the pharma and biotech sectors.
